Hemogenyx Pharmaceuticals PLC COVID-19 Project Update (8905P)
2020年6月15日 - 3:00PM
RNSを含む英国規制内ニュース (英語)
TIDMHEMO
RNS Number : 8905P
Hemogenyx Pharmaceuticals PLC
15 June 2020
Hemogenyx Pharmaceuticals plc
(the "Company")
COVID-19 Project Update
Hemogenyx Pharmaceutical plc is pleased to announce progress in
relation to its COVID-19 program.
On 24 June 2019, the Company announced the completion of the
development of its second generation Advanced peripheral blood
Hematopoietic Chimera ( " ApbHC " ) or advanced humanised mice
which offer several advantages over existing humanised mouse
models. In particular, ApbHC do not develop Graft versus Host
Disease ( " GvHD " ), which can compromise the utility of other
similar types of humanised mice. The Directors considered that
AbpHC, in addition to their use for disease modelling and drug
testing, could potentially be used as a tool for the rapid
discovery of human antibodies against human specific viral
pathogens.
Subsequent work through the Company's subsidiary, Immugenyx, LLC
( " Immugenyx " ), had produced positive preliminary results prior
to the emergence of COVID-19. In light of the emergence of the
current major pandemic, work has been refocussed on COVID-19 with
the aim of producing an effective treatment for those infected with
the virus, and Immugenyx is currently taking the necessary steps to
take this forward effectively. The work involves transplanting
cells from blood samples from patients who have already recovered
from COVID-19 into the ApbHC. This process will allow the Company's
scientists to recreate a set of anti-SARS-CoV-2 virus antibodies
which could be used for the treatment of COVID-19 sufferers.
In view of the continuing international spread of the disease
and the propensity for coronaviruses to mutate and produce new
strains, the Company's technology, in combination with the use of
its humanised mice, should also form the basis for the treatment of
future viral outbreaks.
Meanwhile, as announced on 22 April 2020, the Company has
progressed its work, currently using blood samples from
convalescent patients, to attempt to establish why some individuals
who are infected with SARS-CoV-2 are asymptomatic, some exhibit
mild symptoms, and some become very sick. This work will be of
value in developing new forms of treatment, and especially in
managing infection risk and assisting individuals better to
establish their real risk of getting sick.
The additional funds raised recently have enabled the Company to
take these and other developments forward significantly and at a
faster pace.
At the same time, the Directors are aware of shareholder
interest in the collaboration with Orgenesis Inc. ("Orgenesis").
The Board reminds shareholders of the collaboration agreement
entered into by Immugenyx and Orgenesis in 2018, the principal
terms of which are set out in the Company's announcement of 19
October 2018, and under which Orgenesis obtained the right to use
and distribute the Company's Advanced Humanised Mice.
The Directors welcome Oregenesis' recent announcement of their
own COVID-19 related program and look forward to working with them
under the terms of the collaboration agreement as and when they are
ready to progress this planned development.
Dr Vladislav Sandler, CEO & Co-Founder of Hemogenyx
Pharmaceuticals, commented: " We are pleased with the Company's
on-going developments in relation to COVID-19 and potentially with
other viruses in the future. The treatment of emerging and
re-emerging viral diseases requires ready and effective solutions
for the range of medical problems they create. Our work is designed
to provide such solutions both for the present and for the future.
"
Market Abuse Regulation (MAR) Disclosure
Certain information contained in this announcement would have
been deemed inside information for the purposes of Article 7 of
Regulation No 596/2014 until the release of this announcement.
Enquiries:
Hemogenyx Pharmaceuticals plc hemogenyx.com
Dr Vladislav Sandler, Chief Executive Officer & Co-Founder headquarters@hemogenyx.com
Peter Redmond, Director
SP Angel Corporate Finance LLP Tel: +44 (0)20 3470 0470
Matthew Johnson, Vadim Alexandre, Soltan Tagiev
Peterhouse Capital Limited Tel: +44 (0)20 7469 0930
Lucy Williams, Duncan Vasey, Charles Goodfellow
US Media enquiries Tel: +1 (323) 646-3249
Lowell Goodman lowell@corbomitecomms.com
About Hemogenyx Pharmaceuticals plc
Hemogenyx Pharmaceuticals plc is a publicly traded company (LSE:
HEMO) headquartered in London, with its US operating subsidiaries,
Hemogenyx LLC and Immugenyx LLC, located at its state-of-the-art
research facility in New York City and a Belgian operating
subsidiary, Hemogenyx-Cell SPRL, located in Liège.
Hemogenyx Pharmaceuticals plc is a pre-clinical stage
biopharmaceutical group developing new medicines and treatments to
treat blood and autoimmune disease and to bring the curative power
of bone marrow transplantation to a greater number of patients
suffering from otherwise incurable life-threatening diseases. The
Company is developing several distinct and complementary product
candidates, as well as a platform technology that it uses as an
engine for novel product development.
For more than 50 years, bone marrow transplantation has been
used to save the lives of patients suffering from blood diseases.
The risks of toxicity and death that are associated with bone
marrow transplantation, however, have meant that the procedure is
restricted to use only as a last resort. Hemogenyx Pharmaceuticals
plc's technology has the potential to enable many more patients
suffering from devastating blood diseases such as leukemia and
lymphoma, as well as severe autoimmune diseases such as multiple
sclerosis, aplastic anemia and systemic lupus erythematosus
(Lupus), to benefit from bone marrow transplantation.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
UPDFFFILRDISLII
(END) Dow Jones Newswires
June 15, 2020 02:00 ET (06:00 GMT)
Hemogenyx Pharmaceuticals (LSE:HEMO)
過去 株価チャート
から 6 2024 まで 7 2024
Hemogenyx Pharmaceuticals (LSE:HEMO)
過去 株価チャート
から 7 2023 まで 7 2024